Previous studies have revealed that BRCA1-mutation carriers are at an increased risk of breast, ovarian, prostate, and colon cancers, whereas those of the BRCA2 mutation are at a higher risk of male breast, pancreatic, and prostate cancers.34 The pathogenesis of YSTs remains unclear. Here, BRCA2 is linked to prostate cancer.